Dissecting the Polygenic Basis of Primary Hypertension: Identification of Key Pathway-Specific Components

Carlo Maj*†, Erika Salvi2†, Lorena Citterio3†, Oleg Borisov1, Marco Simonini3, Valeria Glorioso4, Cristina Barlassina1, Nicola Glorioso5, Lutgarde Thijs6, Tatiana Kuznetsova7, Francesco P. Cappuccio8, Zhen-Yu Zhang9, Jan A. Staessen9,10, Daniele Cusi11,12, Chiara Lanzani3 and Paolo Manunta3

† These authors have contributed equally to this work and share first authorship.

Introduction and Objectives: Genome-wide association studies have identified a high number of genetic loci associated with hypertension suggesting the presence of an underlying polygenic architecture. In this study, we aimed to dissect the polygenic component of primary hypertension searching also for pathway-specific components.

Methods: The polygenic risk score (PRS) models, based on the UK biobank genetic component of primary hypertension searching also for pathway-specific components.

Results: The resulting genome-wide PRS was capable of stratifying the individuals for hypertension risk by comparing between individuals in the last PRS decile and the median decile: we observed an odds ratio (OR) of 3.62, CI = [2.01, 6.32] (P = 9.01E-07) and 3.22, 95% CI = [2.06, 5.10] (P = 6.47E-08) in the target and validation cohorts, respectively. The relatively high case/control ORs across PRS quantiles corroborates the presence of strong polygenic components which could be driven by an enrichment of risk alleles within the cases but also by potential enrichment of protective alleles in the old normotensive controls. Moreover, novel pathway-specific PRS revealed an enrichment of the polygenic signal attributable to specific biological pathways. Among those the most significantly associated with hypertension status was the calcium signaling pathway together with other mainly related such as the phosphatidylinositol/inositol phosphate pathways.
INTRODUCTION

Essential hypertension is the major cardiovascular risk factor and its prevalence is constantly increasing worldwide in middle or old age (1). Currently hypertension is responsible for an estimated 7.8 million deaths and 143 million disability life years lost worldwide in 2015 (2). Multiple genetic drivers interacting with environmental and lifestyle facilitators underlie the heterogeneous pathophysiology of this complex trait (3, 4) and contribute to the unpredictable responses to antihypertensive drug treatment (5, 6).

In a complex multifactorial disorder, individual gene variants with small effect per se are generally not informative for assessing disease risk. Advances in understanding the genetics of blood pressure (BP) confirmed that individual genetic loci have modest effects on BP (<1.0 mmHg) and no clinical meaning in the population (6, 7). However, recent genome-wide association studies (GWAS) consortia increased power to identify different new loci for BP by expanding the numbers of studies included in meta-analyses, leading to a higher number of genetic determinants associated with various BP-related traits (8, 9). A genetic loading conferred by the combined set of risk variants was successfully used to obtain a measure to discriminate high risk subjects (10). The information across loci can be combined through the polygenic risk score (PRS), a weighted sum of the number of risk alleles carried by each individual (11, 12). The combination of all BP elevating alleles could increase SBP by approximately 10 mmHg between the top and bottom quintiles of the PRS distribution, substantially increasing risk of cardiovascular events with ORs of about 1.5 (8) in two large cohorts of European ancestry. Recently, PRS associated with incident hypertension in a population based-cohort with the highest 2.5% PRS had a 2.3-fold risk of hypertension and 10.6 years earlier hypertension onset compared to individuals with an average PRS (13) and with a higher incidence of adverse cardiovascular events (14). PRS are usually derived from several variants across the genome without investigation on the underlying biological mechanism (15). However, the computation of pathway-specific PRS investigates to which extent the genetic variability located in genes belonging to specific biological processes is driving the genome-wide PRS associations (16, 17). While a classic genome-wide PRS combining the effects of all hypertension-associated SNPs may be more powerful for corroborating the presence of a highly polygenic genetic signal for hypertension, a pathway-specific PRS may be a more powerful predictor of specific biomarkers contributing to an enriched component of the underlying hypertension pathology, thus leading to a greater comprehension of individual hypertension predisposition.

In the present work, we computed both a genome-wide and a Kyoto Encyclopedia of Genes and Genomes (KEGG) derived pathway-specific PRS for hypertension in a Caucasian case/control target cohort. The derived models were then applied to an independent validation cohort in association with hypertension status. Furthermore, the analysis of hypertension pathway-specific PRS in the target and in the validation HYPERGENES cohorts revealed some pathways characterized by a prominent genetic association.

METHODS

Study Design and Participants

Data originate from the multicenter international study “HYPERGENES–European Network for Genetic-Epidemiological Studies: building a method to dissect complex genetic traits, using essential hypertension as a disease model,” funded by the European Union 7th Framework Programme (grant HEALTH-2007-201550) (18). For the present study, we selected primary hypertensive cases having diastolic BP (DBP) ≥ 90 mmHg or systolic BP (SBP) ≥ 140 mmHg or under antihypertensive treatment before the age of 50. On the contrary, normotensives had never been treated for hypertension, presenting DBP < 90 mmHg and SBP < 140 mmHg with more than 50 years of age. As target sample, 1,292 samples from Italy cohorts were selected, divided into 561 hypertensives (43.4%) and 731 normotensives (56.6%) (Table 1). As validation cohort, an independent multi-countries European-based dataset was used including 1,284 cases (57.2%) and 960 controls (42.8%) (Table 1). For both datasets, as expected by the inclusion criteria, the mean age was significantly higher in normotensives than in hypertensives. Since aging is associated with an increased prevalence of hypertension, we selected exclusively hypertensives older than 50-year-old allowing for the exclusion of subjects that developed hypertension at a later age. For this reason, the distribution of age was bimodal and we excluded it as an explanatory variable in the PRS. Moreover, the DBP and SBP pressures were also significantly higher in hypertensives with respect to controls. All participants were unrelated and of European ancestry.

Genotyping Data

Samples were genotyped using Illumina 1M-Duo array. As the data were already used for a GWAS on hypertension we refer the readers to the previous work for details on genotyping data generation (18). In the present work data were re-imputed using V3 of 1,000 genomes project (19). Details on genotype data processing can be found in the Supplementary Material.

Conclusions: The development of pathway-specific PRS could prioritize biological mechanisms, according to their contribution to the genetic susceptibility, whose regulations might be a potential pharmacological preventive target.

Keywords: hypertension, genome-wide association studies, polygenic risk score, prediction, pathway analysis
**Polygenic Risk Score**

PRS was computed using a clumping-thresholding approach by means of PRSice software (20). The pipeline generates clumps around SNPs (by considering flanking genomic regions of 250 kb) with P-value of associations lower than a given threshold and retain only variants that are not in linkage with the indexed variants (variants with an r2 of correlations > 0.1 were considered in linkage). The process is repeated iteratively through all index SNPs, starting from the smallest P-value and allowing each SNP to appear only in one clump. A PRS so defined contains the most significantly phenotype-associated SNPs (according to the reference GWAS) for each linkage-disequilibrium (LD) filtered clump across the entire genome. The PRS is then computed as the weighted sum of the risk alleles, where the weights represent the strength of association with the phenotype as represented by the beta coefficients of the reference genome-wide summary statistics (i.e., reference base associations for the PRS).

Polygenic risk score for hypertension were built according to the variant effect sizes retrieved from the GWAS on hypertension performed on UK Biobank dataset including 144,793 cases and 313,761 controls (21). The summary statistics from UK Biobank GWAS were used as base associations (i.e., to match variant names and corresponding genomic coordinates and to derive the betas from the GWAS to be used as weights of the tested alleles). Different PRS were created over a range of five P-values thresholds, from genome wide to full model, namely (1.0, 0.5, 0.05, 1E-4, 1E-6, 5E-8).

The PRS models are based on logistic regression analysis of hypertension case/control status considering PRS as explanatory variable and including sex, BMI and the first 4 principal components as covariates to adjust for potential residual population stratification. In order to assess the relative importance of PRS the partial Nagelkerke’s pseudo-R2 is computed as the difference between the R2 of the full model including covariates and PRS and the only covariates model. The best fitting model was selected according to the higher partial R2. The flowchart for the study methodology is available as Figure 1.

In order to test for the prediction performance of the models the receiving operating curves (ROC) were derived and the corresponding area under the curves (AUC) were computed. The DeLong’s test was applied to compare the AUC of the full models and of the covariate-models and thus to assess the additional specific contribution in the prediction performance attributable to the PRS.

**Pathway-Specific PRS**

Beside genome-wide PRS also pathway-specific PRS were generated by associating variants to genes according to chromosome coordinates as implemented in PRSet (20), http://www.prset.info/prset_detail/. Both exonic and intronic variants were mapped to genes and considered in the pathway-specific PRS (intergenic variants were excluded). The genes associated with essential hypertension were analyzed for functional significance in the various metabolic pathways using the KEGG (Kyoto Encyclopedia of Genes and Genomes-http://www.genome.jp/kegg/) (22). A total of 186 KEGG pathways were considered in the analysis using the Molecular Signatures Database v7.1 (https://www.gsea-msigdb.org/gsea/msigdb/).

Since pathway-specific PRS are based on a small number of variants, full models (i.e., no P-value filtering) after clumping were generated for each pathway so to capture the overall genetic signal present in the pathway, an approach proved to be effective to obtain to study pathways-specific associations (23). False discovery rate was applied to correct for multiple-testing. Beside self-contained P-values also pathway-specific competitive P-values were generated through a permutation based-approach aimed at the evaluation of a potential enrichment in the genetic signal attributable to specific gene-sets. Namely a background set of SNPs is defined by considering all variants belonging to any genes and thus included for pathway-specific PRS. The pathway specific P-value is compared to the null distribution of P-values obtained by randomly selecting n times (where n is the number of permutations) k variants from the background set (where k is number of variants in the analyzed pathway specific PRS).

In the present work 10k permutations were applied to derive the empirical P-values (i.e., competitive P-values) used to assess to which extent the genetic signal is enriched in a given pathway with respect to the underlying genome-wide association signal.

The z-score for each pathway was derived as the ratio between the PRS effect size and standard error of the corresponding logistic regression while the Pearson correlation coefficient of the

---

**TABLE 1 | Demographic and phenotypic characteristics of target and validation cohorts.**

| Variable | Target (N = 1,292) | Validation (N = 2,244) |
|----------|--------------------|------------------------|
|          | Male | Age (Years) | BMi (kg/m²) | Systolic BP (mmHg) | Diastolic BP (mmHg) | Male | Age (Years) | BMi (kg/m²) | Systolic BP (mmHg) | Diastolic BP (mmHg) |
|          | 432 (77.0%) | 45.5 (±7.97) | 26.4 (±3.02) | 148.6 (±8.93) | <0.001 | 801 (62.4%) | 49.6 (±9.8) | 27.6 (±4.3) | 154.8 (±14.9) | <0.001 |
|          | 426 (58.3%) | 59.5 (±6.1) | 25.1 (±3.3) | 124.9 (±6.8) | <0.001 | 575 (59.5%) | 62.6 (±9.96) | 26.1 (±3.8) | 122.5 (±10.04) | <0.001 |

Continuous variables are presented as mean and standard deviation, categorical variables as numbers and percentages. Between-groups comparisons of continuous variables were performed using t-test. Categorical data were compared between groups using the chi-squared test.
z-scores was used to assess the correlation of the pathway-specific PRS in the target and in the validation cohort.

RESULTS

Polygenic Risk Score

A logistic regression analysis including PRS and adjusted for sex, BMI and 4 Principal Components was implemented. A strong association between the PRS and hypertension status in the target Italian cohort was detected considering all the analyzed P-value thresholds (Figure 2). The best fitting model was based on 2,166 clumped variants (Supplementary Table 1) and reached a P-value of associations of 6.46 E-21 and a partial Nagelkerke R2 of 9.46%. The model was then applied to the validation cohort and the association between PRS and hypertension status was replicated (P-value = 2.92E-41, R2 = 11.64%). The distribution of the PRS in the two cohorts is shown in Supplementary Figure 1.

In order to test to which extent PRS can differentiate individuals for the hypertension risk we stratified the individuals in deciles according to the PRS and we compared the OR across the different groups. Both in the target and in the validation cohort we observed that the higher the decile the higher the OR (Table 2, Figure 3).

The comparison of the ROC in full model and in the covariate-only model in both cohorts showed that PRS improves the discrimination between cases and controls (Figure 4). The AUC of the full model including PRS was significantly greater than the AUC reached by the only covariates model (DeLong's test P = 2.47E-09 and P = 8.97E-12 in the target and in the validation cohort, respectively). Specifically, the AUC of the covariates-only model (thus including BMI, sex and 4PC) reached and AUC of 0.68 and 0.66 in the target and validation cohort, respectively. The inclusion of PRS in the model led to an AUC of 0.75 and 0.73 in the target and in the validation cohort, respectively.

Pathway-Specific PRS

We further examined the pathway-specific PRS for enrichment of the polygenic signal by analyzing the polygenic signal that can be attributed to KEGG pathways by considering variants located in gene-region. A total of 175,488 variants across 11,950 genes were included in pathway analysis. Pathway-specific PRS in the target cohort detected a total of 21 significant (FDR adjusted) associations out of the 186 analyzed KEGG pathways derived-PRS (see Supplementary Table 2). The identified 21 pathway-based PRS were also significantly enriched with respect to the background PRS signal as assessed by the empirical-competitive (Emp_P) P-value. Pathway-specific PRS were also computed in the multi-countries validation cohort by considering the same variants.

A moderate correlation has been observed in the z-scores of pathways-specific PRS in the target cohort (Supplementary Table 2) and in the validation cohort with the Person correlation coefficient equal to 0.34, 95% CI [0.21, 0.34], P-value = 1.67E-07). Of the 21 significant pathways identified in the target cohort, 7 were replicated (see Table 3, Supplementary Table 2). Among those the most significantly associated with hypertension status was the calcium signaling...
pathway ($P_{FDR}$ target = 0.0010, $P_{FDR}$ validation = 0.0012). We also found evidence of enrichment for pathways involved in the phosphatidylinositol signaling system and the inositol phosphate metabolism, in the mammalian target of rapamycin (mTOR) and the vascular endothelial growth factor (VEGF) signaling pathways, and in the focal adhesion and the Huntington disease pathways (Table 2, Supplementary Table 2). Gene-enrichment analysis showed a total of 675 univocal genes (Supplementary Table 3), some of which were shared among five pathways ($n = 4$), four ($n = 14$), three ($n = 18$) or between two pathways ($n = 89$). The most common genes among the pathways were related to the phosphatidylinositol-4,5-bisphosphate 3-kinase, the phosphoinositide-3-kinase regulatory subunit, the inositol-trisphosphate 3-kinase gene families as well as the phospholipase C isoforms and the Akt serine/threonine kinases.

**DISCUSSION**

In the present study a strong association between PRS based on UK Biobank data and the hypertension status was detected in two independent case/control cohorts. The best fitting model was obtained considering 2,167 clumped variants confirming that hypertension is a highly polygenic trait as already verified in other larger cohorts (8, 9).

A recent work describing the association of PRS for BP with incident hypertension in >200,000 of the FinnGenn population based-cohort showed that individuals with the highest 2.5% PRS have a 2.3-fold risk of hypertension and 10.6 years earlier hypertension onset compared to individuals with an average PRS (13). Another PRS for hypertension based on 858 independent SNPs was found to be associated with a higher incidence of adverse cardiovascular events (14) even if to date, PRS are based on data and cohorts composed of largely European-ancestry individuals, and the transferability of their performance for other ethnicities is a particularly important challenge. More recently, PRS for cardiometabolic traits in sub-Saharan Africans in comparison with African Americans and European Americans showed a greater predictive utility for BP traits among Europeans and a poorer performance in Africans (24), maybe reflecting the choice of SNPs and weights for PRS differing between populations due to LD and allele frequency patterns differences.
TABLE 2 | OR for hypertension across PRS deciles.

| PRS decile | OR target | N controls target | N cases target | P target | OR validation | N controls validation | N cases validation | P validation |
|------------|-----------|-------------------|----------------|----------|---------------|-----------------------|--------------------|-------------|
| 1          | 0.44      | 102               | 28             | 2.85E-03 | 0.32          | 155                   | 70                 | 1.03E-08    |
| 2          | 0.56      | 96                | 34             | 3.4E-02  | 0.51          | 132                   | 93                 | 4.73E-04    |
| 3          | 0.82      | 85                | 44             | 0.52     | 0.56          | 126                   | 98                 | 3.35E-03    |
| 4          | 1         | 79                | 50             | 1        | 0.69          | 114                   | 110                | 0.071       |
| 5          | 1         | 79                | 50             | 1        | 1             | 94                    | 130                | 1           |
| 6          | 1.17      | 74                | 55             | 0.61     | 1.03          | 92                    | 132                | 0.92        |
| 7          | 1.76      | 61                | 68             | 3.34E-03 | 1.11          | 88                    | 136                | 0.63        |
| 8          | 1.70      | 62                | 67             | 4.51E-02 | 1.39          | 76                    | 147                | 0.096       |
| 9          | 2.18      | 54                | 75             | 2.72E-03 | 2.21          | 55                    | 169                | 1.31E-04    |
| 10         | 3.62      | 39                | 90             | 9.13E-07 | 3.21          | 41                    | 183                | 6.47E-08    |

Number of controls and cases across PRS decile and corresponding OR and P-values in the target and in the validation cohort.

FIGURE 3 | PRS stratification for hypertension risk. ORs between hypertensive cases and normotensive controls by grouping the samples according to the PRS deciles (A: target cohort; B: validation cohort). The points represent the OR point estimates and the lines represent the corresponding standard errors.

The PRS analysis for hypertension reported in the present work regarded a target and validation case/control samples from HYPERGENES, collected over many years in different European regions. Compared to the above previous results in this framework, the peculiarity of the current samples was the inclusion of older hyper-controls in this cohort previously analyzed for a classical GWAS but not yet for a potential polygenic component (18). Despite the relatively small sample size the presence of individuals with early-onset hypertension and old normotensive controls represent an optimal cohort for a PRS analysis as a prominent genetic component can be expected for a trait otherwise characterized by a predominant environmental component (25). The relatively high case/control ORs across PRS quantiles corroborates the presence of strong polygenic components which could be driven by an enrichment of risk alleles within the cases but also by potential enrichment of protective alleles in the old normotensive controls (26). Furthermore, PRS may identify individuals missed by canonical clinical risk prediction models, particularly those at high risk for early-onset disease, as already seen for most cardiovascular diseases where risk calculators have been trained with data limited on middle-aged individuals (27). In line with this hypothesis, we observed that in HYPERGENES dataset a prediction model for hypertension combining both clinical risk factors (i.e., sex and BMI) and PRS reached a significantly higher AUC with respect to a model based on only covariates.

Beside the primary purpose in the definition of disease status, PRS may be also informative to gain insight into the potential disease-related biological pathways by addressing their genetic contribution in PRS (28).

Our findings reporting the analysis of hypertension pathway-specific PRS in the target and in the validation
FIGURE 4 | Prediction of hypertension. Target (A) and validation (B) ROC of the full model including PRS and covariates (darker line) and of the covariates-only (i.e., BMI, sex and 4PC) model (lighter line).

TABLE 3 | Significant pathway-specific PRS in both target and validation cohorts.

| Set                        | $P_{\text{FDR}}$ target | Z score target | $P_{\text{FDR}}$ validation | Z score validation | N SNP |
|-----------------------------|--------------------------|----------------|-----------------------------|-------------------|-------|
| Calcium signaling           | 0.001                    | 4.40           | 0.0012                      | 4.32              | 1,669 |
| VEGF signaling              | 0.021                    | 3.17           | 0.0035                      | 3.96              | 439   |
| Focal adhesion              | 0.0097                   | 3.54           | 0.014                       | 3.48              | 1,575 |
| Phosphatidylinositol signaling system | 0.01                 | 3.43           | 0.027                       | 3.10              | 758   |
| Huntington’s disease        | 0.037                    | 2.91           | 0.027                       | 3.12              | 799   |
| MTOR signaling              | 0.045                    | 2.78           | 0.033                       | 2.95              | 278   |
| Inositol phosphate metabolism | 0.01                    | 3.45           | 0.0349                      | 2.94              | 439   |

$P_{\text{FDR}}$ target and $P_{\text{FDR}}$ validation refer to P-value in the target cohort and in the validation cohort, respectively; Z score target and Z score validation refer to represent the Z-value of the PRS regression coefficients; N SNP indicates the number of SNPs included to compute the pathway-specific PRS.

HYPERGENES cohorts revealed some pathways characterized by a prominent genetic association. Strikingly, calcium signaling and phosphatidylinositol/inositol phosphate pathways were intuitive candidates that have been extensively implicated in hypertension, whereas others such as the mTOR, the VEGF, the focal adhesion signaling pathways, and particularly the Huntington disease pathways are unexpected. In hypertension, many of the mechanisms regulating intracellular calcium homeostasis are perturbed. Calcium intracellular concentration and signaling control the key functions of vascular smooth muscle cells (VSMCs), leading to activation of the phospholipase C (PLC)-mediated phosphoinositide hydrolysis, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (PLC-IP3-DAG) pathway (29, 30), but also influence activity of many transcription factors and proteins, transporters, channels and exchangers thereby impacting the cellular phenotype and function. Other calcium-independent processes regulating VSMCs contraction influence the calcium sensitization, and include the DAG-PLC-PKC pathway and the RhoA-Rho kinase (ROCK) pathway (31).

The phosphatidylinositol 4,5-bisphosphate 3-kinases (PI3Ks) are common to the inositol phosphate metabolism and to the phosphatidylinositol signaling system. These enzymes mediate intracellular transduction pathways by catalyzing the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) upon several stimuli (32). Furthermore, PI3K signaling has been shown to be involved in many mechanisms related to vascular function, by the activation of protein kinase B (Akt) (33). The second messenger IP3 may activate the endoplasmic reticulum calcium-release channel inositol trisphosphate receptor (IP3R) (34).

In this study, the KEGG pathway enrichment analysis showed that also VEGF pathway was associated with hypertension, generally considered to be the main pathway responsible for
In conclusion, the PRS reported here, which sum up the effect of numerous genetic variants, are capable of stratifying the individuals for hypertension status both in a target and a validation cohort. These findings provide insights into the clinically relevant performance of PRS for case-control discrimination, possibly before the clinical manifestation, as the genetic make-up of an individual is largely stable from birth; therefore, genetic information can potentially be used as an early risk predictor (53). Moreover, we computed pathway-specific PRS to investigate to which extent the genetic variability located in genes belonging to specific biological processes is driving the current genome-wide PRS associations, thus prioritizing biological mechanisms overlapping putative core biological previously studied and newly mechanisms. The advent of clinically relevant polygenic scores and the related biological specific-pathways mechanisms also purposes novel backgrounds for potential pharmacological preventive targeting in several pathologies related to hypertension. Further studies of personalized treatment of each individual could allow randomization to clinical trials and biomarker studies to be stratified based on evidence of involvement of specific biological pathways.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

CM, ES, LC, CL, and PM conceived and designed the project. MS, VG, CB, NG, LT, TK, FC, Z-YZ, JS, DC, CL, and PM recruited the subjects and performed the assessments of patients. CB performed the genotyping. CM and OB analyzed data. CM, ES, and LC wrote the manuscript. CL and PM revised critically the manuscript content. All the authors read and approved the final manuscript.

FUNDING

This work was supported by the HYPERGENES project (European Network for Genetic-Epidemiological Studies: building a method to dissect complex genetic traits, using essential hypertension as a disease model), grant HEALTH-F4-2007-201550, funded by EU within the FP7. CM receives support by the BONFOR-program of the Medical Faculty, University of Bonn (Grant Number O-147.0002.1). APPREMED (URL: http://www.appremed.org) received a non-binding grant from Omron Healthcare Co., Ltd., Kyoto, Japan.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.814502/full#supplementary-material
REFERENCES

1. Oliveira-Paula GH, Pereira SC, Tanus-Santos JE, Lacchini R. Pharmacogenomics and hypertension: current insights. Pharmacogenomics Pers Med. (2019) 12:341–59. doi: 10.2174/PPPM.523020
2. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. (2017) 317:165–82. doi: 10.1001/jama.2016.19043
3. Padmanabhan S, Joe B. Towards precision medicine for hypertension: a review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans. Physiol Rev. (2017) 97:469–528. doi: 10.1152/physrev.00035.2016
4. Pazzoli R, Dehghan A, Evangelou E, Warren H, Gao H, Caulfield M, et al. Genetic predisposition to high blood pressure and lifestyle factors: associations with midlife blood pressure levels and cardiovascular events. Circulation. (2018) 137:653–61. doi: 10.1161/CIRCULATIONAHA.117.030988
5. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. (2015) 386:801–12. doi: 10.1016/S0140-6736(14)61648-9
6. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. (2017) 49:403–15. doi: 10.1038/ng.3768
7. Tragante V, Barnes MR, Ganesh SK, Laukktree MB, Guo W, Franceschini N, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. Am J Hum Genet. (2014) 94:349–60. doi: 10.1016/ajhg.2013.12.016
8. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazzoli R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. (2018) 50:1412–25. doi: 10.1038/s41588-018-0205-x
9. Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. Nat Genet. (2019) 51:51–62. doi: 10.1038/s41588-018-0303-9
10. Richardson TG, Harrison S, Hemani G, Davey Smith G. An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome. Elife. (2019) 8:e43657. doi: 10.7554/eLife.43657
11. Khera A V, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. (2018) 50:1219–24. doi: 10.1038/s41588-018-0183-z
12. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Vaura F, Kauko A, Suvila K, Havulinna AS, Mars N, Salomaa V, et al. Polygenic risk score analysis revealed shared genetic background in attention deficit hyperactivity disorder and narcolepsy. Transl Psychiatry. (2020) 10:284. doi: 10.1038/s41398-020-00971-7
13. Tolokon A, Kundi P, Zhang YD, Lan LV, Kim S, Ghandwani D, et al. Combined utility of 25 disease and risk factor polygenic risk scores for stratifying risk of all-cause mortality. Am J Hum Genet. (2020) 107:418–31. doi: 10.1016/j.ajhg.2020.07.002
14. Mars N, Koskela JT, Ripatti P, Kiskinen TTI, Havulinna AS, Lindbom J V, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat Med. (2020) 26:549–57. doi: 10.1038/s41591-020-0880-0
15. Hall A, Bandres-Ciga S, Dier-Fairen M, Quinn JP, Billingsley KI. Genetic risk profiling in parkinson’s disease and utilizing genetics to gain insight into disease-related biological pathways. Int J Mol Sci. (2020) 21:1–15. doi: 10.3390/ijms21197332
16. Goulopoulos S, Webb RC. Symmetry of vascular contraction how smooth muscle cells lose harmony to signal increased vascular resistance in hypertension. Hypertension. (2014) 63:e33–9. doi: 10.1161/HYPERTENSIONAHA.113.02444
17. Misáriková E, Behulák M, Bencez M, Zicha J. Excitation-contraction coupling and excitation-transcription coupling in blood vessels: their possible interactions in hypertensive vascular remodeling. Physiol Res. (2016) 65:173–91. doi: 10.33494/physiols.933317
18. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Rev Cardiol. (2010) 7:637–47. doi: 10.1016/jfcc.2010.136
19. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. (2005) 7:606–19. doi: 10.1038/nrg15879
20. Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. (2004) 29:95–102. doi: 10.1016/j.tibs.2003.12.004
21. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem. (2001) 70:281–312. doi: 10.1146/annurev.biochem.70.1.281
22. Cross MJ, Claesson-Welsh L. FGFR and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. (2001) 22:201–7. doi: 10.1016/s0165-6140(00)01676-x
23. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies—focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. (2015) 9:140–25. doi: 10.1016/j.jsh.2018.03.008
24. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies focus on kinase inhibitors. J Am Coll Cardiol. (2015) 66:1160–78. doi: 10.1016/j.jacc.2015.07.025
25. Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF and its receptor (VEGFR) signaling and associated nephrotoxicities. J Am Soc Nephrol. (2019) 30:187–200. doi: 10.1681/ASN.2018080853
39. Tang DD. The dynamic actin cytoskeleton in smooth muscle. *Adv Pharmacol.* (2018) 81:1–38. doi: 10.1016/bs.apha.2017.06.001
40. Chen CS, Alonso JL, Ostuni E, Whitesides GM, Ingber DE. Cell shape provides global control of focal adhesion assembly. *Biochem Biophys Res Commun.* (2003) 307:355–61. doi: 10.1016/S0006-291X(03)01165-3
41. Ōkuda M, Kawahara Y, Nakayama I, Hoshijima M, Yokoyama M. Angiotensin II transduces its signal to focal adhesions via angiotensin II type 1 receptors in vascular smooth muscle cells. *FEBS Lett.* (1995) 368:343–7. doi: 10.1016/0014-5793(95)00693-4
42. Glading A, Lauffenburger DA, Wells A. Cutting to the chase: calpain proteases in cell motility. *Trends Cell Biol.* (2002) 12:46–54. doi: 10.1016/S0962-8924(01)02179-1
43. Sakuma K, Yamaguchi A. The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle. *J Biomed Biotechnol.* (2010) 2010:721219. doi: 10.1155/2010/721219
44. Lee FY, Zhen YY, Yuen CM, Fan R, Chen YT, Sheu JJ, et al. The mTOR-FAK mechanotransduction signaling axis for focal adhesion maturation and cell proliferation. *Am J Transl Res.* (2017) 9:1603–17.
45. Reho JJ, Rahmouni K. Oxidative and inflammatory signals in obesity-associated vascular abnormalities. *Clin Sci.* (2017) 131:1689–700. doi: 10.1042/CS20170219
46. Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. *Med Clin North Am.* (2017) 101:129–37. doi: 10.1016/j.mcna.2016.08.009
47. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. *J Hypertens.* (2006) 24:1663–70. doi: 10.1097/01.hjh.0000239304.01496.83
48. Gusella JF, MacDonald ME. Huntington’s disease: the case for genetic modifiers. *Genome Med.* (2009) 1:80. doi: 10.1186/gm80
49. Steventon JJ, Rosser AE, Hart E, Murphy K. Hypertension, antihypertensive use and the delayed-onset of huntington’s disease. *Mov Disord.* (2020) 35:937–46. doi: 10.1002/mds.27976
50. Schultz JL, Harshman LA, Langbehn DR, Nopoulos PC. Hypertension is associated with an earlier age of onset of huntington’s disease. *Mov Disord.* (2020) 35:1558–64. doi: 10.1002/mds.28662
51. Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, et al. Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and Non-African populations. *Am J Hum Genet.* (2013) 93:545–54. doi: 10.1016/j.ajhg.2013.07.010
52. Duncan I, Shen H, Gelaye B, Meijisen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. *Nat Commun.* (2019) 10:3328. doi: 10.1038/s41467-019-11112-0
53. Padmanabhan S, Dominiczak AF. Genomics of hypertension: the road to precision medicine. *Nat Rev Cardiol.* (2021) 18:235–50. doi: 10.1038/s41569-020-00466-4

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.